Antigen News and Research

RSS

Novartis to highlight strength of its expanded oncology portfolio at ASCO 2015

Novartis will highlight the strength of its expanded oncology portfolio in 21 medicines and 11 investigational compounds across more than 185 data presentations at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, May 29-June 2, and the Congress of the European Hematology Association (EHA), June 11-14.

1 Jun 2015

New combination chemotherapy may become clinical standard for metastatic castrate-resistant prostate cancer

For more than a decade, oncologists using cytotoxic chemotherapy to treat patients with advanced metastatic castration-resistant prostate cancer (mCRPC) have relied on the sequential use of single agent taxanes such as docetaxel and cabazitaxel. For example, docetaxel is commonly used as the "first-line" therapy, while cabazitaxel is used as the "second-line" therapy.

30 May 2015

Over 700 Chinese patients with acute myeloid leukemia undergo Microtransplantation treatment

According to Dr. Huisheng Ai's team, founder of Microtransplantation regimen mainly for Acute Myeloid Leukemia, over 700 patients have undergone this therapy since its emergence in 2002. Based at MST International Clinic for Leukemia in the 307th Hospital of Chinese People's Liberation Army in Beijing, about 40 hematology centers covering all main hospitals in 32 provinces of mainland China have adopted Microtransplantation regimen.

30 May 2015

TxCell to deliver two presentations on Col-Treg and Ovasave at ISCT Annual Meeting

TxCell SA, a biotechnology company developing innovative, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that Dr. Arnaud Foussat, VP Research and New Products, TxCell, will deliver two presentations at the 21st Annual Meeting of the International Society of Cellular Therapy, May 27-30, 2015, in Las Vegas, Nevada, US.

30 May 2015

Monoclonal antibody nivolumab improves survival rates of melanoma patients

The monoclonal antibody nivolumab has shown promise as a therapeutic agent, particularly by improving the survival rates of melanoma patients. Jeffrey S. Weber, M.D., Ph.D., director of the Donald A. Adam Comprehensive Melanoma Research Center at Moffitt Cancer Center will be presenting data from a retrospective analysis of the safety of nivolumab in 4 ongoing phase I-III studies in melanoma patients at the 2015 American Society of Clinical Oncology Annual Meeting in Chicago.

29 May 2015

Green tea components may help prevent prostate cancer development in at-risk men

Prostate cancer is the second most common type of cancer in men and is predicted to result in an estimated 220,00 cases in the United States in 2015. In recent years, an emphasis has been placed on chemoprevention - the use of agents to prevent the development or progression of prostate cancer.

29 May 2015

TxCell reports results from annual general meeting of shareholders

28 May 2015

Roche announces FDA clearance for cobas Cdiff Test to detect C. difficile in stool specimens

Roche announced today that the US Food and Drug Administration has provided 510(k) clearance for the cobas Cdiff Test to detect Clostridium difficile (C. difficile) in stool specimens.

26 May 2015

Microfluidic cell-squeezing device could introduce specific antigens inside immune system's B cells

MIT researchers have shown that they can use a microfluidic cell-squeezing device to introduce specific antigens inside the immune system's B cells, providing a new approach to developing and implementing antigen-presenting cell vaccines.

22 May 2015

GHIT Fund expands investments in leishmaniasis, diagnostic tests

The Global Health Innovative Technology Fund, which in the last two years has funded almost $32 million for innovative tools to tackle global infectious diseases, today announced additional investments of nearly $11 million that bring its portfolio to approximately $43 million.

22 May 2015

Mi-Prostate Score improves prostate cancer detection

A new urine-based test improved prostate cancer detection - including detecting more aggressive forms of prostate cancer - compared to traditional models based on prostate serum antigen, or PSA, levels, a new study finds.

19 May 2015

BioNTech, Genmab to jointly develop and commercialize immunomodulatory antibodies for cancer

BioNTech AG, a fully integrated biotechnology company developing truly personalized cancer immunotherapies, announces that it has signed an agreement with Genmab A/S to jointly research, develop and commercialize multiple bispecific antibodies for cancer immunotherapy using proprietary technologies from both companies: BioNTech's proprietary immunomodulatory antibodies and Genmab's DuoBody technology platform.

19 May 2015

Pre-pregnancy maternal weight has significant impact on baby's immune system

Almost 60 percent of women of childbearing age in the United States are overweight or obese. Obesity is a major public health issue, and has been linked to health problems like heart disease, cancer and hypertension. It can complicate pregnancy by increasing the mother's risk of having gestational diabetes, preeclampsia, preterm birth or a baby with birth defects. Maternal obesity is also linked to several adverse health outcomes for the infant that can persist into adulthood, such as type-2 diabetes, heart disease and mortality.

19 May 2015

UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015

UCB, a global biopharmaceutical company focusing on immunology and neurology treatment and research, is sponsoring several data presentations on Cimzia (certolizumab pegol) at Digestive Disease Week 2015, taking place in Washington, DC from May 16-19.

17 May 2015

Active surveillance appears to be safer management strategy for prostate cancer patients

Four studies evaluating effectiveness, trends and other considerations for active surveillance in managing prostate cancer will be presented during the 110th Annual Scientific Meeting of the American Urological Association.

17 May 2015

FDA licenses Protein Sciences' Pearl River, NY facility to manufacture Flublok influenza vaccine

Protein Sciences Corporation announced that on May 12, 2015 the U.S. Food and Drug Administration licensed its Pearl River, NY manufacturing facility for the commercial manufacturing of Flublok influenza vaccine. Flublok is the world's first licensed influenza vaccine made using modern recombinant technology.

13 May 2015

Soligenix, Emergent BioSolutions sign development agreement

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it has initiated a development agreement with Emergent BioSolutions to implement a commercially viable, scalable production technology for the RiVax drug substance protein antigen.

13 May 2015

Australian researchers discover rogue germinal centre B cells that trigger autoimmune disease

Australian researchers believe they have discovered a group of cells that trigger autoimmune disease, as well as the molecular 'trigger guard' that normally holds them in check.

13 May 2015

World renowned surgeon evaluates parallels between Prostate cancer, Breast cancer

World renowned robotic prostate cancer surgeon, Dr. David Samadi, evaluates the parallels between Prostate cancer and Breast cancer. Prostate cancer is just as common in men as breast cancer is in women with over 233,000 cases diagnosed each year.

12 May 2015

Dana-Farber/Boston Children's joins immunotherapy clinical trial for children with ALL

Dana-Farber/Boston Children's Cancer and Blood Disorders Center has joined a clinical trial of immunotherapy for children with relapsed or treatment-resistant acute lymphoblastic leukemia (ALL). Led by Memorial Sloan Kettering Cancer Center, the trial is one of several nationally that are evaluating cancer immunotherapy, a treatment approach -- hailed by Science magazine as their Breakthrough of the Year in 2013 -- that triggers a patient's immune system to attack his or her cancer cells.

11 May 2015

Antigen News and Research

Novartis to highlight strength of its expanded oncology portfolio at ASCO 2015

New combination chemotherapy may become clinical standard for metastatic castrate-resistant prostate cancer

Over 700 Chinese patients with acute myeloid leukemia undergo Microtransplantation treatment

TxCell to deliver two presentations on Col-Treg and Ovasave at ISCT Annual Meeting

Monoclonal antibody nivolumab improves survival rates of melanoma patients

Green tea components may help prevent prostate cancer development in at-risk men

TxCell reports results from annual general meeting of shareholders

Roche announces FDA clearance for cobas Cdiff Test to detect C. difficile in stool specimens

Microfluidic cell-squeezing device could introduce specific antigens inside immune system's B cells

GHIT Fund expands investments in leishmaniasis, diagnostic tests

Mi-Prostate Score improves prostate cancer detection

BioNTech, Genmab to jointly develop and commercialize immunomodulatory antibodies for cancer

Pre-pregnancy maternal weight has significant impact on baby's immune system

UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015

Active surveillance appears to be safer management strategy for prostate cancer patients

FDA licenses Protein Sciences' Pearl River, NY facility to manufacture Flublok influenza vaccine

Soligenix, Emergent BioSolutions sign development agreement

Australian researchers discover rogue germinal centre B cells that trigger autoimmune disease

World renowned surgeon evaluates parallels between Prostate cancer, Breast cancer

Dana-Farber/Boston Children's joins immunotherapy clinical trial for children with ALL

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News